William Blair Reiterates Outperform Rating on Xenon Pharmaceuticals (XENE): "we see further room for upside"
Tweet Send to a Friend
William Blair analyst Myles Minter reiterated an Outperform rating and {REMOVEPT} price target on Xenon Pharmaceuticals (NASDAQ: XENE)The analyst commented ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
